RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBThe First FDA-Approved RSV Vaccine for People 60 Years and Older. AREXVY protects against lung and lower airway infection caused by respiratory syncytial virus (RSV).
About AREXVY | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBAREXVY is the first FDA-approved vaccine used to prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”
RSV Vaccine | AREXVY (Respiratory Syncytial Virus Vaccine, …
WEBAREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.
AREXVY | FDA - U.S. Food and Drug Administration
WEBJun 2, 2023 · Approval History, Letters, Reviews, and Related Documents - AREXVY. For active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in ...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
WEBAug 17, 2023 · AREXVY is indicated for the prevention of RSV-lower respiratory tract disease (LRTD) in individuals aged 60 years and older. Under the Inflation Reduction Act, patients with Medicare Part D will pay no out-of-pocket expenses.
US FDA approves GSK’s Arexvy, the world’s first respiratory …
WEBMay 3, 2023 · US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults. Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time. The approval is based on data from the positive pivotal AReSVi-006 phase III trial that showed exceptional efficacy ...
US FDA approves expanded age indication for GSK’s AREXVY, the …
WEBJun 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for the prevention of RSV lower respiratory tract disease (LRTD) in adults 50 through 59 years of age who are at increased risk.
WEBGSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk. Application supported by positive results of a phase III trial showing immune response and acceptable tolerability profile in …
- Some results have been removed